Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27.
Article
Google Scholar
Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Solano Villarreal ML, et al. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. Mol Genet Metab. 2016;119(1–2):131–43.
Article
CAS
Google Scholar
Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. 1990;87(5):1913–6.
Article
CAS
Google Scholar
Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229–40.
Article
Google Scholar
Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101.
Article
CAS
Google Scholar
Giugliani R, Lampe C, Guffon N, Ketteridge D, Leao-Teles E, Wraith JE, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)—10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A. 2014;164A(8):1953–64.
Article
Google Scholar
Harmatz P, Whitley CB, Wang RY, Bauer M, Song W, Haller C, et al. A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488–94.
Article
CAS
Google Scholar
Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10:131.
Article
Google Scholar
Sparks TNLB, Adami RR, et al. Exome sequencing for prenatal diagnosis in non-immune hydrops fetalis. N Engl J Med. 2020;383:1746–56.
Article
CAS
Google Scholar
Giugliani RDC A, Poswar F, Vanzella C, Horovitz D, Riegel M, Baldo G, Vairo F. Intrathecal/Intracerebroventricular enzyme replacement therapy for the mucopolysaccharidoses: efficacy, safety, and prospects. Expert Opin Orphan Drugs. 2018;6(7):403–11.
Article
Google Scholar
Sands MS, Vogler C, Torrey A, Levy B, Gwynn B, Grubb J, et al. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Invest. 1997;99(7):1596–605.
Article
CAS
Google Scholar
Salazar-Fontana LI, Desai DD, Khan TA, Pillutla RC, Prior S, Ramakrishnan R, et al. Approaches to mitigate the unwanted immunogenicity of therapeutic proteins during drug development. AAPS J. 2017;19(2):377–85.
Article
CAS
Google Scholar
Nguyen QH, Witt RG, Wang B, Eikani C, Shea J, Smith LK, et al. Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with Mucopolysaccharidosis type VII. Sci Transl Med. 2020. https://doi.org/10.1126/scitranslmed.aay8980.
Article
PubMed
PubMed Central
Google Scholar
Sabatino DE, Mackenzie TC, Peranteau W, Edmonson S, Campagnoli C, Liu YL, et al. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. Mol Ther. 2007;15(9):1677–85.
Article
CAS
Google Scholar
Nijagal A, Wegorzewska M, Jarvis E, Le T, Tang Q, MacKenzie TC. Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice. J Clin Invest. 2011;121(2):582–92.
Article
CAS
Google Scholar
Waddington SN, Buckley SM, Nivsarkar M, Jezzard S, Schneider H, Dahse T, et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood. 2003;101(4):1359–66.
Article
CAS
Google Scholar
Peranteau WH, Hayashi S, Abdulmalik O, Chen Q, Merchant A, Asakura T, et al. Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants. Blood. 2015;126(10):1245–54.
Article
CAS
Google Scholar
Burke W, Appelbaum P, Dame L, Marshall P, Press N, Pyeritz R, et al. The translational potential of research on the ethical, legal, and social implications of genomics. Genet Med. 2015;17(1):12–20.
Article
Google Scholar
Young A, Menon D, Street J, Al-Hertani W, Stafinski T. Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. Orphanet J Rare Dis. 2017;12(1):188.
Article
Google Scholar
Lowe MM, Blaser DA, Cone L, Arcona S, Ko J, Sasane R, et al. Increasing patient involvement in drug development. Value Health. 2016;19(6):869–78.
Article
Google Scholar
Freedman R, Sahhar M, Curnow L, Lee J, Peters H. Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families. J Genet Couns. 2013;22(4):517–32.
Article
CAS
Google Scholar
Koto Y, Ueki S, Yamakawa M, Sakai N. Experiences of patients with lysosomal storage disorders treated with enzyme replacement therapy: a qualitative systematic review protocol. JBI Evid Synth. 2020;19(3):702–8.
Article
Google Scholar
Lahr A. Analysis of parent perception of newborn screening for lysosomal storage disorders. Doctoral dissertation, University of Pittsburgh. 2020.
Almeida-Porada G, Waddington SN, Chan JKY, Peranteau WH, MacKenzie T, Porada CD. In utero gene therapy consensus statement from the IFeTIS. Mol Ther. 2019;27(4):705–7.
Article
CAS
Google Scholar
Massaro G, Mattar CNZ, Wong AMS, Sirka E, Buckley SMK, Herbert BR, et al. Fetal gene therapy for neurodegenerative disease of infants. Nat Med. 2018;24:1317–23.
Article
CAS
Google Scholar
Harvey ME, David AL, Dyer J, Spencer R. Pregnant women’s experiences and perceptions of participating in the EVERREST prospective study; a qualitative study. BMC Pregnancy Childbirth. 2019;19(1):144.
Article
Google Scholar
Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genet Med. 2003;5(4):286–94.
Article
CAS
Google Scholar
Gilkes J, Patterson B, Heldermon C. Mucopolysaccharidosis III: molecular genetics and genotype-phenotype correlations. OA Genet. 2014;2(1):1.
Google Scholar
Hutchesson AC, Bundey S, Preece MA, Hall SK, Green A. A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands. UK J Med Genet. 1998;35(5):366–70.
Article
CAS
Google Scholar
Wilson JL, Cheung KWK, Lin L, Green EAE, Porras AI, Zou L, et al. Scientific considerations for global drug development. Sci Transl Med. 2020. https://doi.org/10.1126/scitranslmed.aax2550.
Article
PubMed
PubMed Central
Google Scholar
Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–37.
Article
CAS
Google Scholar
Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis. 2013;36(2):373–84.
Article
Google Scholar
Rothman BK. The products of conception: the social context of reproductive choices. J Med Eth. 1985;11(4):188–95.
Article
CAS
Google Scholar
Casper MJ. The making of the unborn patient: a social anatomy of fetal surgery. New Brunswick, NJ: Rutgers University Press; 1998.
Google Scholar
Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120.
Article
CAS
Google Scholar
Dilger H, Leissner L, Bosanska L, Lampe C, Plockinger U. Illness perception and clinical treatment experiences in patients with M Maroteaux-Lamy (mucopolysaccharidosis type VI) and a Turkish migration background in Germany. PLoS ONE. 2013;8(6):e66804.
Article
CAS
Google Scholar
Aldenhoven M, van den Broek BTA, Wynn RF, O’Meara A, Veys P, Rovelli A, et al. Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. Blood Adv. 2017;1(24):2236–42.
Article
CAS
Google Scholar
Conner T, Cook F, Fernandez V, Rascati K, Rangel-Miller V. An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States. Orphanet J Rare Dis. 2019;14(1):48.
Article
Google Scholar
Pentek M, Gulacsi L, Brodszky V, Baji P, Boncz I, Pogany G, et al. Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. Eur J Health Econ. 2016;17(Suppl 1):89–98.
Article
Google Scholar
Somanadhan S, Larkin PJ. Parents’ experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS). Orphanet J Rare Dis. 2016;11(1):138.
Article
CAS
Google Scholar
Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating benefit-risk decision-making in spinal muscular atrophy: a first-ever study to assess risk tolerance in the SMA patient community. Clin Ther. 2019;41(5):943–60.
Article
Google Scholar
Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27(5):428–38.
Article
Google Scholar
Green ED, Gunter C, Biesecker LG, Di Francesco V, Easter CL, Feingold EA, et al. Strategic vision for improving human health at The Forefront of Genomics. Nature. 2020;586(7831):683–92.
Article
CAS
Google Scholar